Alkermes

ALKS

Biotechnology · Healthcare

Price

$52.72

+0.78 (+1.50%)

Market Cap

$8.79B

Exchange

NASDAQ

Winston Score

Winston is serious

Mixed quality — meaningful strengths and weaknesses.

Share count rising — dilution

+4.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 160.9M (2021) → 168.7M (2025)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; IN

Winston Score History

Politician Trades

3 trades / 12mo

1 Congressional buy and 2 sells on ALKS in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+28.2% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

-385.7% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$324M/ year

↑ Rising (+32% vs prior year)

22.0% of revenue

In line with sector average (18%)

Investing heavily in future products and technology

Insider Activity

7.6%ownership

↑ Rising

Insiders increasing their stake — aligned with shareholders

Cash Runway

~6 months

$352M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Revenue accelerating

Alkermes grew revenue 28% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

84.3%

Premium pricing power — 84.3% gross margin

Operating Margin

-12.3%

Losing money on operations — -12.3%

ROCE

-1.5%

Weak — -1.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+3.2%

Slow sales growth (3.2% YoY)

EPS YoY

-56.7%

Earnings shrinking (-56.7% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

168%

Turns 168% of profit into real cash

FCF Margin

14.2%

Converts sales into free cash efficiently (14.2%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.86

Moderate — manageable debt (0.86)

Interest Cover

5.79x

Adequate interest coverage (5.8x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

56.7x

Expensive — P/E 56.7

P/E over 35. The market is pricing in heavy, sustained growth.

P/E vs Forward

+16.9

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (56.7 → 39.8)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial